INVESTIGADORES
URTREGER Alejandro Jorge
congresos y reuniones científicas
Título:
Norcantharidin, preclinical settings of a new player for triple negative breast cancer treatment
Autor/es:
LIZETH ARIZA BAREÑO; DAMIAN DELBART; AGUSTINA TARUSELLI; ANDRES BECHIS; MARIA J. COSTA; LAURA B. TODARO; ALEJANDRO J. URTREGER
Lugar:
Mar del Plata
Reunión:
Congreso; LXIV Reunión Científica de la Sociedad Argentina de Investigación Clínica (SAIC); 2019
Institución organizadora:
Sociedad Argentina de Investigación Clínica (SAIC)
Resumen:
Triple negative breast cancer (TNBC) is a subgroup of mammary cancer that do not express estrogen or progesterone receptors and neither overexpress the HER2 receptor. These tumors are very aggressive, and patients present high recurrence and metastasis rates.It has been described that Norcantharidin (NCTD) can inhibit the progression of several types of cancer however, the effect on breast cancer has not been studied yet. For this reason, we have evaluated the effect of NCTD on human (HS578T) and murine (4T1) TNBC cell lines.NCTD exhibited an important antiproliferative effect, with an IC50 of 56 uM for HS578T and 35 uM for 4T1 cell lines, obtained by MTS assay. This antiproliferative effect was consequence of a time-sustained reduction in ERK activated levels (p-ERK) as well as an increase in the Sub-G0 cell cycle fraction, compatible with the presence of apoptotic cells.In both cell lines, NCTD significantly reduced adhesive and migratory capacities (p 0.05, Anova test) also displaying an important reduction in MMP-9 secreted activity. Although these parameters could have a direct implication in the malignant progression, clonogenic and in vivo assays showed an inverse behavior. In this regard, the pretreatment of 4T1 cells with NCTD induced an increase in the number of in vitro colonies and no effect could be detected in the amount of experimental lung metastatic nodes.Even though some results obtained are encouraging, we must seek the appropriated therapeutic strategy, probably combining with another drug, in order to allow and effective use of NCTD for the treatment of triple negative breast cancer.